# A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease

> **NCT06734234** · PHASE1 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 84 (estimated)

## Conditions studied

- Kidney Disease

## Interventions

- **DRUG:** GSK4771261
- **DRUG:** Placebo matching GSK4771261

## Key facts

- **NCT ID:** NCT06734234
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-11
- **Primary completion:** 2026-09-04
- **Final completion:** 2026-09-04
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06734234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06734234, "A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06734234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*